Moderna agreed to a settlement with Genevant Sciences and Arbutus Biopharma that could total up to $2.25 billion to resolve patent claims over lipid nanoparticle (LNP) delivery technology used in its Spikevax COVID‑19 vaccine. Under terms reported by MedCity News, Moderna will pay $950 million upfront and obtain a global non-exclusive license for LNP technology in infectious disease vaccines; additional payments are contingent on legal appeals and specified conditions. The deal closes a high-profile intellectual property dispute that had posed commercial and legal uncertainty for mRNA vaccine delivery platforms and may reshape licensing dynamics for LNP technologies across the industry.